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Objectives: To report early and late outcomes of
segmental resection and graft replacement of the inferior
vena cava (IVC) for malignant disease.
Methods: All patients who had IVC resection with
graft reconstruction from 1990 to 2013 were reviewed. Pa-
tients with tangential excision and primary or patch venor-
rhaphy were excluded. End points were early (<30 days)
mortality, major adverse events (MAE), graft-related com-
plications, primary patency, and recurrence-free and overall
survival.
Results: Among 2305 patients treated for retroperito-
neal malignancy, 102 (50% male; age, 56 6 15 years) had
IVC resection and graft replacement (prosthetic in 100).
Primary leiomyosarcoma occurred in 33 patients (32%)
and other malignancies in 69 (68%; P < .0001). Preopera-
tive performance status (Eastern Cooperative Oncology
Group) was good or excellent in 92 patients (90%). Resec-
tion of multiple IVC segments was required in 59 patients
(58%), 24 who needed renal vein reconstruction (24%) and
two who had hepatic vein reimplantation. One patient died
of intraoperative hemorrhage. Four others died #4
months, one procedure-related from duodenal leak and
multisystem organ failure. Fifteen patients had MAE
(15%), two graft-related. Over a mean follow-up of 56
months, seven patients had graft occlusion (6.9%). At 5-
years, overall survival was 51% (range, 1-214 months), local
recurrence-free survival was 66%, and disease-free survival
was 35%. Four patients underwent graft-related reinterven-
tions (4%). Kaplan-Meier estimates of IVC graft primary
patency were 95%, 92%, and 92% at 1, 3, and 5 years,
respectively.
Conclusions: IVC resection and graft replacement for
malignant disease is safe, durable and provides excellent
local control of the tumor in select patients.
Author Disclosures: T. C. Bower: Nothing to disclose; S.
Cha: Nothing to disclose; K. J. Cherry: Nothing to
disclose; R. R. De Martino: Nothing to disclose; A. A.
Duncan: Nothing to disclose; M. D. Fleming: Nothing
to disclose; P. Gloviczki: Nothing to disclose; M. Kalra:
Nothing to disclose; B. C. Mendes: Nothing to disclose;
D. M. Nagorney: Nothing to disclose; G. S. Oderich:
Nothing to disclose; B. J. Toomey: Nothing to disclose.C8a: Poster SessiondAortic Disease (1)
PS2
Type Ia Endoleaks Following Fenestrated and
Branched Endografts May Lead to component
instability and increased mortality
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Objectives: Fenestrated and branched endografts
facilitate sealing in the visceral aorta to extend the landing
zone for complex aneurysms. We describe the causes and
implications of proximal endoleak in our experience.
Methods: All patients undergoing fenestrated/
branched repair were entered onto a prospective database.
Inclusion criteria necessitated the availability of at least one
postoperative contrast computed tomography scan. Three-
dimensional imaging was used to characterize morphology
and correlated with outcome. Blinded assessors resized the
repairs in the endoleak group to assess the change in prac-
tice from early repairs to current practice. Outcome mea-
sures were mortality and a composite of stent fracture,
type III and Ic endoleak, as an indicator of device stability.
Results: Up to July 2013, 969 patients underwent
fenestrated/branched repair. Emergency repairs (n ¼ 24)
and patients without requisite imaging (n ¼ 21) were
excluded, leaving 924 available for analysis. A type Ia endo-
leak was identiﬁed in 23 patients (2.5%). Landing zone
choice was implicated as cause of endoleak development,
because sealing in the visceral aorta was associated with endo-
leak development (52.2% vs 24.5%, P ¼ .006). Aortic-related
mortality was higher in the endoleak group, 30% vs 7%
respectively (P ¼ .001), and they experienced a higher inci-
dence of component instability, 34.8 vs 9.5% (P ¼ .001).
Conclusions: Fenestrated/branched endovascular
repair has a low incidence of sealing zone failure despite
the increased complexity. Choice of proximal landing
zone may predict occurrence of endoleak. Development
of a proximal endoleak seems to destabilize the repair
and may lead to increased mortality.
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Objectives: Endovascular aneurysm repair (EVAR)
has become the primary treatment for abdominal aortic
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ventions compared with open repair. This study compares
the outcomes from EVAR and open repair in the Vascular
Study Group of New England (VSGNE).
Methods: We reviewed all elective, nonruptured
symptomatic, and ruptured endovascular and open repairs
of AAA from 2003-2012. Postoperative reinterventions,
morbidity, and mortality were compared at the 30-day,
30-day to 1-year, and overall 1-year follow-up.
Results: We identiﬁed 3347 EVARs and 2251 open
repairs. At 30 days and 1 year, overall reintervention rates
were higher after open repair compared with EVAR (Ta-
ble). Between 30 days and 1 year, reinterventions were
less after elective open repair compared with EVAR (2.6%
vs 3.8%, P ¼ .03) but were similar after open repair and
EVAR for symptomatic (4.5% vs 4.6%, P ¼ .97) and
ruptured (5.5% vs 4.3%, P ¼ .58) AAA. Mortality was
lower after elective EVAR compared with open repair at
30 days (1.6% vs 2.6%, P ¼ .01) but was similar at 1 year
(7.2% vs 7.3%, P ¼ .88).
Conclusions: Reintervention was more common after
open repair compared with EVAR across all AAA repair in
the perioperative period. Between 30 days and 1 year,
EVAR had higher reintervention rates for elective AAA
repair but was similar to open repair for symptomatic and
ruptured AAA.
Table. Reintervention rates for all patients undergoing
endovascular aneurysm repair (EVAR) vs open
abdominal aortic aneurysm repair
EVAR Open
Reinterventions (n ¼ 3347) (%) (n ¼ 2251) (%) P30-day reinterventions 1.9 11.5 <.01
Multiple reinterventions 0.3 2.2 <.01
Leg embolization 0.8 1.6 <.01
Bowel ischemia 0.5 2.5 <.01
Wound complication 0.4 3.1 <.01
Hemorrhage 0.6 2.7 <.01
Return to operating room 10.8 10.9 <.01(n ¼ 3002) (n ¼ 2140)
30-day to 1-year reinterventions 3.8 3.3 .29
Multiple reinterventions 1.3 0.6 <.01
Total 1-year reinterventions 5.5 13.2 <.01Author Disclosures: R. Bensley: Nothing to disclose; C.
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Objectives: The purpose of this study is to determine
the cost differences associated with different intravenous
(IV) blood pressure medications used in the treatment of
acute Stanford type B aortic dissections.
Methods: A retrospective record review was conduct-
ed of patients treated for an acute type B aortic dissection
between June 2006 and September 2013 to determinethe IV blood pressure medication regimen (a combination
of labetalol, esmolol, nitroprusside, and/or nicardipine).
Patients receiving each IV infusion were compared with pa-
tients not receiving that drug with regards to the total cost
of the infusion, mortality, the complication rate associated
with the dissection, and the need for operation.
Results: Ninety patients were treated with IV blood
pressure medications for an acute type B dissection. The
in-hospital mortality rate was 11.1%, 33.3% experienced a
complication of their dissection, and 4.4% had an operation
after an initial attempt at medical therapy. Fifty-three
percent of patients received an esmolol infusion, 46% a
nicardipine infusion, 41% a labetalol infusion, and 54% a
nitroprusside infusion. Median cost of admission was
$66,355 (interquartile range, $41,372-$160,176), and
median cost of the infusions was $4837 (interquartile
range, $1922-$13,240). Esmolol was associated with
increased total drug cost (median, $10,545 vs $1947; P
< .001) and longer intensuve care unit (ICU) stays (me-
dian, 5 vs 3 days; P ¼ .025). Nicardipine carried increased
cost ($11,195 vs $3365, P < .001) and longer ICU stay (5
vs 3 days, P ¼ .058). Labetalol carried decreased cost (me-
dian $3931 vs $9136, P ¼ .004) with no difference in ICU
stay (3 vs 3 days; P ¼ .175). Nitroprusside carried no dif-
ference in cost ($5095 vs $4038; P ¼ .182). No drug
was associated with increased mortality, need for operation,
or complication of the dissection.
Conclusions: Labetalol and nitroprusside are signiﬁ-
cantly cheaper medications to treat acute type B aortic dis-
sections, and they are not associated with increased risk of
death, complication of the dissection, or need for
operation.
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Objectives: We sought to demonstrate the prognostic
implication of ﬂap thickness (FT) in type B aortic dissection
(TBAD).
Methods: A retrospective review was undertaken of all
patients with TBAD from June 2006 to June 2012. Demo-
graphics, hospital course, imaging, and follow-up visits
were analyzed. FT on computed tomography angiography
(CTA) was measured using full width at half maximum
technique. Survival rates and predictors of outcome were
determined using the Kaplan-Meier method with Cox pro-
portional hazards.
Results: Of 134 patients with TBAD, 101 (75%) had a
classical dissection and 33 (24%) had atypical dissection (no
dissection ﬂap). FT analysis was available in 63 patients (38
men), with a mean age of 646 15 years. Median follow-up
was 33 (0-135) months. Sixteen patients underwent
